| Name | Title | Contact Details |
|---|
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians and scientists in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side`s scientific corridor, Weill Cornell Medicine`s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine-Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria, and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Lower Manhattan Hospital, and NewYork-Presbyterian Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. At Weill Cornell Medicine, we connect the collective power of our integrated partners in education and research to provide world-class care for our individual patients—#CareDiscoverTeach.
Verim Research is a Hood River, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
Ardea Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ReadiVet is a mobile veterinary service that provides professional vet services in the comfort of your home.